Vertex links up with Entrada for myotonic dystrophy program

8 December 2022

US biotech Vertex Pharmaceuticals (Nasdaq: VRTX), best known as a big player in the cystic fibrosis field, has entered another licensing deal aiming to extend its range of therapeutic interests.

Today, Vertex announced a global collaboration with fellow USA-based biotech Entrada Therapeutics (Nasdaq: TRDA) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1), a form of muscular dystrophy that affects muscles and many other organs in the body

The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage pre-clinical development, and news of the deal pushed the firm’s shares up more than 17% to $20.78 by mid-morning trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK